Medicines in Development for Arthritis
Read More About Arthritis
America’s biopharmaceutical research companies are currently developing 198 medicines to help the more than 50 million Americans afflicted with at least one of the 100 different musculoskeletal disorders, including arthritis. All of the medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration.
- 67 for rheumatoid arthritis that affects about 1.3 million American adults.
- 23 for osteoporosis that affects 10 million people, 80 percent of whom are women.
- 19 for lupus which affects an estimated 1.5 million Americans.
- 19 for osteoarthritis, the most common form of arthritis, affecting nearly 27 million Americans.
- 15 for musculoskeletal pain that affects the muscles, ligaments, tendons, and bones.
- 9 for fibromyalgia which affects 3 million to 6 million Americans.
- A new monoclonal antibody in development for lupus modulates B-cells that produce antibodies against the body’s own cells and tissue, causing the immune system to turn on itself.
- A medicine in development for rheumatoid arthritis (RA) that inhibits two types of an enzyme that are key components in signaling activation of cytokines and growth factors that are elevated in patients with RA.
- A potential first-in-class medicine in development for pain associated with osteoarthritis that is an inhibitor of a gene-encoding protein that plays a role in inflammatory pain.
- Approximately 294,000 children under the age of 18 are affected by pediatric arthritis and rheumatologic conditions.*
- State prevalence numbers for pediatric arthritis and rheumatologic conditions are available in the “Prevalence of and Annual Ambulatory Health
- Care Visits for Pediatric Arthritis and Other Rheumatologic Conditions in the US in 2001-2004”.*
- Ambulatory care visits for pediatric arthritis and rheumatologic conditions averaged 827,000 annually.*
- Juvenile arthritis is one of the most common childhood diseases in the United States.*
- Arthritis and related conditions, such as juvenile arthritis, cost the U.S. economy nearly $128 billion per year in medical care and indirect expenses, including lost wages and productivity.*